SAGE Therapeutics Inc (NASDAQ:SAGE) has earned a consensus rating of “Buy” from the eighteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $199.27.

A number of research analysts recently issued reports on SAGE shares. ValuEngine upgraded shares of SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cowen reiterated a “buy” rating on shares of SAGE Therapeutics in a research note on Thursday, May 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price target on shares of SAGE Therapeutics in a research note on Thursday, May 3rd. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Finally, LADENBURG THALM/SH SH started coverage on shares of SAGE Therapeutics in a research note on Wednesday, June 6th. They issued a “buy” rating and a $230.00 price target for the company.

Shares of SAGE Therapeutics traded up $0.96, reaching $148.36, during trading on Tuesday, MarketBeat.com reports. The company’s stock had a trading volume of 233,107 shares, compared to its average volume of 394,225. SAGE Therapeutics has a 1-year low of $59.57 and a 1-year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.84) by $1.48. The business had revenue of $90.00 million during the quarter. research analysts predict that SAGE Therapeutics will post -7.86 EPS for the current year.

Several large investors have recently modified their holdings of the company. Two Sigma Advisers LP purchased a new stake in SAGE Therapeutics in the 4th quarter valued at $2,125,000. Allianz Asset Management GmbH increased its stake in SAGE Therapeutics by 962.4% in the 1st quarter. Allianz Asset Management GmbH now owns 44,474 shares of the biopharmaceutical company’s stock valued at $7,163,000 after buying an additional 40,288 shares during the period. UBS Group AG increased its stake in SAGE Therapeutics by 242.6% in the 1st quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock valued at $3,785,000 after buying an additional 16,636 shares during the period. Swiss National Bank increased its stake in SAGE Therapeutics by 19.8% in the 1st quarter. Swiss National Bank now owns 79,400 shares of the biopharmaceutical company’s stock valued at $12,789,000 after buying an additional 13,100 shares during the period. Finally, Northern Trust Corp increased its stake in SAGE Therapeutics by 11.1% in the 1st quarter. Northern Trust Corp now owns 493,595 shares of the biopharmaceutical company’s stock valued at $79,503,000 after buying an additional 49,437 shares during the period.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.